img

Global and United States Peptide and Oligonucleotide CDMO Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global and United States Peptide and Oligonucleotide CDMO Market Report & Forecast 2024-2034

Market Analysis and InsightsGlobal and United States Peptide and Oligonucleotide CDMO Market
This report focuses on global and United States Peptide and Oligonucleotide CDMO market, also covers the segmentation data of other regions in regional level and county level.
The global Peptide and Oligonucleotide CDMO revenue was US$ 1600 million in 2022 and is forecast to a readjusted size of US$ 3117.9 million by 2033 with a CAGR of 10.0% during the review period (2023-2033).
In United States the Peptide and Oligonucleotide CDMO revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The global key players of Peptide and Oligonucleotide CDMO include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd. and Ajinomoto Co., Inc., etc. The global five biggest players hold a share of % in 2022.
Global Peptide and Oligonucleotide CDMO Scope and Market Size
Peptide and Oligonucleotide CDMO market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Peptide and Oligonucleotide CDMO market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For United States market, this report focuses on the Peptide and Oligonucleotide CDMO market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in United States.



By Company


Lonza Group Ltd.
Thermo Fisher Scientific Inc.
Merck KGaA
Catalent, Inc.
Genscript Biotech Corporation
Polypeptide Group
Bachem Holding AG
Wuxi Apptec Co., Ltd.
Ajinomoto Co., Inc.
Rentschler Biopharma SE
Corden Pharma GmbH
Senn Chemicals AG
Almac Group
Lonza Custom Manufacturing
Creative Peptides
Swiss Customized Synthesis
Syngene
Eurogentec
Segment by Type
Peptide CDMO
Oligonucleotide CDMO

Segment by Application


Pharmaceutical and Biotechnology Companies
Research Institutes
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Peptide and Oligonucleotide CDMO definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Peptide and Oligonucleotide CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Peptide and Oligonucleotide CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide and Oligonucleotide CDMO revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Peptide and Oligonucleotide CDMO Product Introduction
1.2 Global Peptide and Oligonucleotide CDMO Outlook 2018 VS 2022 VS 2033
1.2.1 Global Peptide and Oligonucleotide CDMO Market Size for the Year 2018-2033
1.2.2 United States Peptide and Oligonucleotide CDMO Market Size for the Year 2018-2033
1.3 Peptide and Oligonucleotide CDMO Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.3.1 The Market Share of United States Peptide and Oligonucleotide CDMO in Global, 2018 VS 2022 VS 2033
1.3.2 The Growth Rate of Peptide and Oligonucleotide CDMO Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.4 Peptide and Oligonucleotide CDMO Market Dynamics
1.4.1 Peptide and Oligonucleotide CDMO Industry Trends
1.4.2 Peptide and Oligonucleotide CDMO Market Drivers
1.4.3 Peptide and Oligonucleotide CDMO Market Challenges
1.4.4 Peptide and Oligonucleotide CDMO Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Peptide and Oligonucleotide CDMO by Type
2.1 Peptide and Oligonucleotide CDMO Market Segment by Type
2.1.1 Peptide CDMO
2.1.2 Oligonucleotide CDMO
2.2 Global Peptide and Oligonucleotide CDMO Market Size by Type (2018, 2022 & 2033)
2.3 Global Peptide and Oligonucleotide CDMO Market Size by Type (2018-2033)
2.4 United States Peptide and Oligonucleotide CDMO Market Size by Type (2018, 2022 & 2033)
2.5 United States Peptide and Oligonucleotide CDMO Market Size by Type (2018-2033)
3 Peptide and Oligonucleotide CDMO by Application
3.1 Peptide and Oligonucleotide CDMO Market Segment by Application
3.1.1 Pharmaceutical and Biotechnology Companies
3.1.2 Research Institutes
3.1.3 Others
3.2 Global Peptide and Oligonucleotide CDMO Market Size by Application (2018, 2022 & 2033)
3.3 Global Peptide and Oligonucleotide CDMO Market Size by Application (2018-2033)
3.4 United States Peptide and Oligonucleotide CDMO Market Size by Application (2018, 2022 & 2033)
3.5 United States Peptide and Oligonucleotide CDMO Market Size by Application (2018-2033)
4 Global Peptide and Oligonucleotide CDMO Competitor Landscape by Company
4.1 Global Peptide and Oligonucleotide CDMO Market Size by Company
4.1.1 Global Key Companies of Peptide and Oligonucleotide CDMO, Ranked by Revenue (2022)
4.1.2 Global Peptide and Oligonucleotide CDMO Revenue by Player (2018-2023)
4.2 Global Peptide and Oligonucleotide CDMO Concentration Ratio (CR)
4.2.1 Peptide and Oligonucleotide CDMO Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Peptide and Oligonucleotide CDMO in 2022
4.2.3 Global Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Peptide and Oligonucleotide CDMO Head office and Area Served
4.4 Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application
4.5 Global Key Players of Peptide and Oligonucleotide CDMO, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Peptide and Oligonucleotide CDMO Market Size by Company
4.7.1 Key Players of Peptide and Oligonucleotide CDMO in United States, Ranked by Revenue (2022)
4.7.2 United States Peptide and Oligonucleotide CDMO Revenue by Players (2021, 2022 & 2023)
5 Global Peptide and Oligonucleotide CDMO Market Size by Region
5.1 Global Peptide and Oligonucleotide CDMO Market Size by Region: 2018 VS 2022 VS 2033
5.2 Global Peptide and Oligonucleotide CDMO Market Size by Region (2018-2033)
5.2.1 Global Peptide and Oligonucleotide CDMO Market Size by Region: 2018-2023
5.2.2 Global Peptide and Oligonucleotide CDMO Market Size by Region (2024-2033)
6 Americas
6.1 Americas Peptide and Oligonucleotide CDMO Market Size YoY Growth 2018-2033
6.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type
6.2.1 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
6.2.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
6.2.3 Americas Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
6.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application
6.3.1 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.3.2 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
6.3.3 Americas Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
6.4 Americas Peptide and Oligonucleotide CDMO Market Facts & Figures by Country (2018, 2022 & 2033)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Peptide and Oligonucleotide CDMO Market Size YoY Growth 2018-2033
7.2 EMEA Peptide and Oligonucleotide CDMO Market Size by Type
7.2.1 EMEA Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
7.2.2 EMEA Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
7.2.3 EMEA Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
7.3 EMEA Peptide and Oligonucleotide CDMO Market Size by Application
7.3.1 EMEA Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
7.3.2 EMEA Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
7.3.3 EMEA Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
7.4 EMEA Peptide and Oligonucleotide CDMO Market Facts & Figures by Country (2018, 2022 & 2033)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Peptide and Oligonucleotide CDMO Market Size YoY Growth 2018-2033
8.2 China Peptide and Oligonucleotide CDMO Market Size by Type
8.2.1 China Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
8.2.2 China Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
8.2.3 China Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
8.3 China Peptide and Oligonucleotide CDMO Market Size by Application
8.3.1 China Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
8.3.2 China Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
8.3.3 China Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
9 APAC (excluding China)
9.1 APAC Peptide and Oligonucleotide CDMO Market Size YoY Growth 2018-2033
9.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type
9.2.1 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
9.2.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
9.2.3 APAC Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
9.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application
9.3.1 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
9.3.2 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
9.3.3 APAC Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
9.4 APAC Peptide and Oligonucleotide CDMO Market Facts & Figures by Country (2018, 2022 & 2033)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Lonza Group Ltd.
10.1.1 Lonza Group Ltd. Company Details
10.1.2 Lonza Group Ltd. Business Overview
10.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Introduction
10.1.4 Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.1.5 Lonza Group Ltd. Recent Development
10.2 Thermo Fisher Scientific Inc.
10.2.1 Thermo Fisher Scientific Inc. Company Details
10.2.2 Thermo Fisher Scientific Inc. Business Overview
10.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Introduction
10.2.4 Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.2.5 Thermo Fisher Scientific Inc. Recent Development
10.3 Merck KGaA
10.3.1 Merck KGaA Company Details
10.3.2 Merck KGaA Business Overview
10.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Introduction
10.3.4 Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.3.5 Merck KGaA Recent Development
10.4 Catalent, Inc.
10.4.1 Catalent, Inc. Company Details
10.4.2 Catalent, Inc. Business Overview
10.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Introduction
10.4.4 Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.4.5 Catalent, Inc. Recent Development
10.5 Genscript Biotech Corporation
10.5.1 Genscript Biotech Corporation Company Details
10.5.2 Genscript Biotech Corporation Business Overview
10.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Introduction
10.5.4 Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.5.5 Genscript Biotech Corporation Recent Development
10.6 Polypeptide Group
10.6.1 Polypeptide Group Company Details
10.6.2 Polypeptide Group Business Overview
10.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Introduction
10.6.4 Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.6.5 Polypeptide Group Recent Development
10.7 Bachem Holding AG
10.7.1 Bachem Holding AG Company Details
10.7.2 Bachem Holding AG Business Overview
10.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Introduction
10.7.4 Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.7.5 Bachem Holding AG Recent Development
10.8 Wuxi Apptec Co., Ltd.
10.8.1 Wuxi Apptec Co., Ltd. Company Details
10.8.2 Wuxi Apptec Co., Ltd. Business Overview
10.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Introduction
10.8.4 Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.8.5 Wuxi Apptec Co., Ltd. Recent Development
10.9 Ajinomoto Co., Inc.
10.9.1 Ajinomoto Co., Inc. Company Details
10.9.2 Ajinomoto Co., Inc. Business Overview
10.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Introduction
10.9.4 Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.9.5 Ajinomoto Co., Inc. Recent Development
10.10 Rentschler Biopharma SE
10.10.1 Rentschler Biopharma SE Company Details
10.10.2 Rentschler Biopharma SE Business Overview
10.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Introduction
10.10.4 Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.10.5 Rentschler Biopharma SE Recent Development
10.11 Corden Pharma GmbH
10.11.1 Corden Pharma GmbH Company Details
10.11.2 Corden Pharma GmbH Business Overview
10.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Introduction
10.11.4 Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.11.5 Corden Pharma GmbH Recent Development
10.12 Senn Chemicals AG
10.12.1 Senn Chemicals AG Company Details
10.12.2 Senn Chemicals AG Business Overview
10.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Introduction
10.12.4 Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.12.5 Senn Chemicals AG Recent Development
10.13 Almac Group
10.13.1 Almac Group Company Details
10.13.2 Almac Group Business Overview
10.13.3 Almac Group Peptide and Oligonucleotide CDMO Introduction
10.13.4 Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.13.5 Almac Group Recent Development
10.14 Lonza Custom Manufacturing
10.14.1 Lonza Custom Manufacturing Company Details
10.14.2 Lonza Custom Manufacturing Business Overview
10.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Introduction
10.14.4 Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.14.5 Lonza Custom Manufacturing Recent Development
10.15 Creative Peptides
10.15.1 Creative Peptides Company Details
10.15.2 Creative Peptides Business Overview
10.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Introduction
10.15.4 Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.15.5 Creative Peptides Recent Development
10.16 Swiss Customized Synthesis
10.16.1 Swiss Customized Synthesis Company Details
10.16.2 Swiss Customized Synthesis Business Overview
10.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Introduction
10.16.4 Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.16.5 Swiss Customized Synthesis Recent Development
10.17 Syngene
10.17.1 Syngene Company Details
10.17.2 Syngene Business Overview
10.17.3 Syngene Peptide and Oligonucleotide CDMO Introduction
10.17.4 Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.17.5 Syngene Recent Development
10.18 Eurogentec
10.18.1 Eurogentec Company Details
10.18.2 Eurogentec Business Overview
10.18.3 Eurogentec Peptide and Oligonucleotide CDMO Introduction
10.18.4 Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
10.18.5 Eurogentec Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Peptide and Oligonucleotide CDMO Market Size United States VS Global, CAGR (2018 VS 2022 VS 2033)
Table 2. Peptide and Oligonucleotide CDMO Market Trends
Table 3. Peptide and Oligonucleotide CDMO Market Drivers
Table 4. Peptide and Oligonucleotide CDMO Market Challenges
Table 5. Peptide and Oligonucleotide CDMO Market Restraints
Table 6. Global Peptide and Oligonucleotide CDMO Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 7. United States Peptide and Oligonucleotide CDMO Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 8. Global Peptide and Oligonucleotide CDMO Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 9. United States Peptide and Oligonucleotide CDMO Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 10. Global Key Companies of Peptide and Oligonucleotide CDMO, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Peptide and Oligonucleotide CDMO Revenue by Player, (US$ Million), 2018-2023
Table 12. Global Peptide and Oligonucleotide CDMO Revenue Share by Player, 2018-2023
Table 13. Global Peptide and Oligonucleotide CDMO Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Peptide and Oligonucleotide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)
Table 15. Global Key Players of Peptide and Oligonucleotide CDMO, Headquarters and Area Served
Table 16. Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application
Table 17. Global Key Players of Peptide and Oligonucleotide CDMO, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Peptide and Oligonucleotide CDMO in United States, Ranked by Revenue (2022) & (US$ Million)
Table 20. United States Peptide and Oligonucleotide CDMO Revenue by Players, (US$ Million), 2021, 2022 & 2023
Table 21. United States Peptide and Oligonucleotide CDMO Revenue Share by Players, 2021, 2022 & 2023
Table 22. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 23. Global Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 24. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Region (2024-2033) & (US$ Million)
Table 25. Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 26. Americas Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 27. Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 28. Americas Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 29. Americas Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 30. Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 31. Americas Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 32. EMEA Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 33. EMEA Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 34. EMEA Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 35. EMEA Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 36. EMEA Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. EMEA Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 38. EMEA Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 39. China Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 40. China Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 41. China Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 42. China Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 43. China Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 45. APAC Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 46. APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 47. APAC Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 48. APAC Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 49. APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 50. APAC Peptide and Oligonucleotide CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 51. Lonza Group Ltd. Company Details
Table 52. Lonza Group Ltd. Business Overview
Table 53. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product
Table 54. Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 55. Lonza Group Ltd. Recent Development
Table 56. Thermo Fisher Scientific Inc. Company Details
Table 57. Thermo Fisher Scientific Inc. Business Overview
Table 58. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product
Table 59. Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 60. Thermo Fisher Scientific Inc. Recent Development
Table 61. Merck KGaA Company Details
Table 62. Merck KGaA Business Overview
Table 63. Merck KGaA Peptide and Oligonucleotide CDMO Product
Table 64. Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 65. Merck KGaA Recent Development
Table 66. Catalent, Inc. Company Details
Table 67. Catalent, Inc. Business Overview
Table 68. Catalent, Inc. Peptide and Oligonucleotide CDMO Product
Table 69. Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 70. Catalent, Inc. Recent Development
Table 71. Genscript Biotech Corporation Company Details
Table 72. Genscript Biotech Corporation Business Overview
Table 73. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product
Table 74. Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 75. Genscript Biotech Corporation Recent Development
Table 76. Polypeptide Group Company Details
Table 77. Polypeptide Group Business Overview
Table 78. Polypeptide Group Peptide and Oligonucleotide CDMO Product
Table 79. Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 80. Polypeptide Group Recent Development
Table 81. Bachem Holding AG Company Details
Table 82. Bachem Holding AG Business Overview
Table 83. Bachem Holding AG Peptide and Oligonucleotide CDMO Product
Table 84. Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 85. Bachem Holding AG Recent Development
Table 86. Wuxi Apptec Co., Ltd. Company Details
Table 87. Wuxi Apptec Co., Ltd. Business Overview
Table 88. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product
Table 89. Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 90. Wuxi Apptec Co., Ltd. Recent Development
Table 91. Ajinomoto Co., Inc. Company Details
Table 92. Ajinomoto Co., Inc. Business Overview
Table 93. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product
Table 94. Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 95. Ajinomoto Co., Inc. Recent Development
Table 96. Rentschler Biopharma SE Company Details
Table 97. Rentschler Biopharma SE Business Overview
Table 98. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product
Table 99. Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 100. Rentschler Biopharma SE Recent Development
Table 101. Corden Pharma GmbH Company Details
Table 102. Corden Pharma GmbH Business Overview
Table 103. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product
Table 104. Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 105. Corden Pharma GmbH Recent Development
Table 106. Senn Chemicals AG Company Details
Table 107. Senn Chemicals AG Business Overview
Table 108. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product
Table 109. Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 110. Senn Chemicals AG Recent Development
Table 111. Almac Group Company Details
Table 112. Almac Group Business Overview
Table 113. Almac Group Peptide and Oligonucleotide CDMO Product
Table 114. Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 115. Almac Group Recent Development
Table 116. Lonza Custom Manufacturing Company Details
Table 117. Lonza Custom Manufacturing Business Overview
Table 118. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product
Table 119. Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 120. Lonza Custom Manufacturing Recent Development
Table 121. Creative Peptides Company Details
Table 122. Creative Peptides Business Overview
Table 123. Creative Peptides Peptide and Oligonucleotide CDMO Product
Table 124. Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 125. Creative Peptides Recent Development
Table 126. Swiss Customized Synthesis Company Details
Table 127. Swiss Customized Synthesis Business Overview
Table 128. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product
Table 129. Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 130. Swiss Customized Synthesis Recent Development
Table 131. Syngene Company Details
Table 132. Syngene Business Overview
Table 133. Syngene Peptide and Oligonucleotide CDMO Product
Table 134. Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 135. Syngene Recent Development
Table 136. Eurogentec Company Details
Table 137. Eurogentec Business Overview
Table 138. Eurogentec Peptide and Oligonucleotide CDMO Product
Table 139. Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 140. Eurogentec Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide and Oligonucleotide CDMO Product Picture
Figure 2. Global Peptide and Oligonucleotide CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Peptide and Oligonucleotide CDMO Market Size 2018-2033 (US$ Million)
Figure 4. United States Peptide and Oligonucleotide CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 5. United States Peptide and Oligonucleotide CDMO Market Size 2018-2033 (US$ Million)
Figure 6. United States Peptide and Oligonucleotide CDMO Market Share in Global 2018-2033
Figure 7. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 8. Product Picture of Peptide CDMO
Figure 9. Product Picture of Oligonucleotide CDMO
Figure 10. Global Peptide and Oligonucleotide CDMO Market Share by Type in 2022 & 2033
Figure 11. Global Peptide and Oligonucleotide CDMO Market Size by Type (2018-2033) & (US$ Million)
Figure 12. Global Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 13. United States Peptide and Oligonucleotide CDMO Market Share by Type in 2022 & 2033
Figure 14. United States Peptide and Oligonucleotide CDMO Market Size by Type (2018-2033) & (US$ Million)
Figure 15. United States Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 16. Product Picture of Pharmaceutical and Biotechnology Companies
Figure 17. Product Picture of Research Institutes
Figure 18. Product Picture of Others
Figure 19. Global Peptide and Oligonucleotide CDMO Market Share by Application in 2022 & 2033
Figure 20. Global Peptide and Oligonucleotide CDMO Market Size by Application (2018-2033) & (US$ Million)
Figure 21. Global Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 22. United States Peptide and Oligonucleotide CDMO Market Share by Application in 2022 & 2033
Figure 23. United States Peptide and Oligonucleotide CDMO Market Size by Application (2018-2033) & (US$ Million)
Figure 24. United States Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 25. The Top 5 and 10 Largest Companies of Peptide and Oligonucleotide CDMO in the World: Market Share by Peptide and Oligonucleotide CDMO Revenue in 2022
Figure 26. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Region: 2018 VS 2022 VS 2033
Figure 27. Global Peptide and Oligonucleotide CDMO Market Share by Region (2018-2033)
Figure 28. Americas Peptide and Oligonucleotide CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 29. Americas Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 30. Americas Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 31. United States Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 32. Canada Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 33. Mexico Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 34. Brazil Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 35. EMEA Peptide and Oligonucleotide CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 36. EMEA Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 37. EMEA Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 38. Europe Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 39. Middle East Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 40. Africa Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 41. China Peptide and Oligonucleotide CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 42. China Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 43. China Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 44. APAC Peptide and Oligonucleotide CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 45. APAC Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 46. APAC Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 47. Japan Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 48. South Korea Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 49. China Taiwan Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 50. Southeast Asia Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 51. India Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 52. Lonza Group Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 53. Thermo Fisher Scientific Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 54. Merck KGaA Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 55. Catalent, Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 56. Genscript Biotech Corporation Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 57. Polypeptide Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 58. Bachem Holding AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 59. Wuxi Apptec Co., Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 60. Ajinomoto Co., Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 61. Rentschler Biopharma SE Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 62. Corden Pharma GmbH Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 63. Senn Chemicals AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 64. Almac Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 65. Lonza Custom Manufacturing Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 66. Creative Peptides Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 67. Swiss Customized Synthesis Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 68. Syngene Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 69. Eurogentec Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries